following a full submission:
lenvatinib (Lenvima®) is accepted for use within NHSScotland.
Indication under review: As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.
In a phase III study in patients with unresectable hepatocellular carcinoma who had not received treatment for advanced disease, lenvatinib was non-inferior to another multikinase inhibitor for overall survival.
SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of lenvatinib and is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
- Medicine name:
- lenvatinib (Lenvima)
- SMC ID:
as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 08 April 2019